Key timing considerations: Side effect profile tends to be somewhat milder than semaglutide, which may reduce the importance of sleep-through timing Same 48-hour minimum spacing rule applies if changing injection days Pre-filled pen format means no reconstitution time, making spontaneous timing adjustments easier Many dulaglutide users report minimal side effects after the first month, at which point timing becomes purely a convenience decision Retatrutide (weekly injectable, investigational) Dosing frequency: Once weekly Half-life: Data from Phase 2 trials suggest approximately 6 days Peak concentration: Approximately 24 to 72 hours after injection Recommended timing approach: As a triple agonist (GLP-1/GIP/glucagon), retatrutide may produce a different side effect profile than pure GLP-1 or dual GLP-1/GIP agonists
[39] Nestor, J
If orforglipron receives approval for obesity in April 2026, it will enter a market that Morgan Stanley estimates could reach $100 billion annually by the early 2030s, potentially transforming Eli Lilly's already dominant position in the metabolic disease space
A study of success rates from 2011 to 2020 showed only 15% of metabolic drugs that started human studies reached the market
Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue
Wegovy: At a Glance Exploring Weight Management Options Medications like Wegovy and Imcivree highlight how treatment approaches for obesity can vary depending on the underlying cause and an individuals health history
